GERN (Geron Corp)
Insider Trading Activity
Every open-market purchase and sale reported by GERN officers, directors and 10%+ beneficial owners on SEC Form 4, which must be filed within two business days of the transaction. Sales often reflect scheduled 10b5-1 plans or tax withholding rather than a directional view, so read counts alongside the size and the filer.
Market data may be delayed, incomplete, or inaccurate. Not a recommendation to buy, sell, or hold any security. Verify quotes with your broker before trading. See Terms §17.
| Filed | Insider | Role | Type | Shares | Value |
|---|---|---|---|---|---|
| 2026-07-01 | Robert J. Spiegel | Director | A | — | — |
| 2026-05-26 | Robert J. Spiegel | Director | A | — | — |
| 2026-05-26 | Susan Molineaux | Director | A | — | — |
| 2026-05-26 | Elizabeth G. O'Farrell | Director | A | — | — |
| 2026-05-26 | John F McDonald | Director | A | — | — |
| 2026-05-26 | Dawn Carter Bir | Director | A | — | — |
| 2026-04-14 | Timothy Williams | EVP and Chief Legal Officer | A | — | — |
| 2026-04-01 | Robert J. Spiegel | Director | A | — | — |
| 2026-03-26 | Patricia S Andrews | Director | A | — | — |
| 2026-03-26 | Constantine Chinoporos | Director | A | — | — |
| 2026-02-19 | Joseph Eid | EVP, R&D; Chief Medical Office | A | — | — |
| 2026-02-19 | MICHELLE ROBERTSON | EVP, CHIEF FINANCIAL OFFICER | MIXED | — | — |
| 2026-01-05 | Robert J. Spiegel | Director | A | — | — |
| 2025-10-20 | Ahmed ElNawawi | EVP, Chief Commercial Officer | A | — | — |
| 2025-10-01 | Robert J. Spiegel | Director | A | — | — |
| 2025-08-08 | Harout Semerjian | President and CEO | A | — | — |
| 2025-07-01 | Robert J. Spiegel | Director | A | — | — |
| 2025-05-22 | Gaurav Aggarwal | Director | A | — | — |
| 2025-05-22 | Susan Molineaux | Director | A | — | — |
| 2025-05-22 | V BRYAN LAWLIS | Director | A | — | — |
| 2025-05-22 | John F McDonald | Director | A | — | — |
| 2025-05-22 | Dawn Carter Bir | Interim President and CEO | A | — | — |
| 2025-05-22 | Elizabeth G. O'Farrell | Director | A | — | — |
| 2025-05-22 | Robert J. Spiegel | Director | A | — | — |
| 2025-05-13 | V BRYAN LAWLIS | Director | Buy | — | — |
| 2025-04-02 | Robert J. Spiegel | Director | A | — | — |
| 2025-04-02 | Robert J. Spiegel | Director | A | — | — |
| 2025-04-02 | Robert J. Spiegel | Director | A | — | — |
| 2025-04-02 | Robert J. Spiegel | Director | A | — | — |
| 2025-03-03 | Scott Alan Samuels | EVP, Chief Legal Officer | Buy | — | — |
| 2025-03-03 | JOHN A SCARLETT | Chairman, President and CEO | Buy | — | — |
| 2025-03-03 | James Ziegler | EVP, Chief Commercial Officer | Buy | — | — |
| 2025-02-20 | ANDREW J GRETHLEIN | EVP, Chief Operating Officer | A | — | — |
| 2025-02-20 | JOHN A SCARLETT | Chairman, President and CEO | A | — | — |
| 2025-02-20 | Scott Alan Samuels | EVP, Chief Legal Officer | A | — | — |
| 2025-02-20 | James Ziegler | EVP, Chief Commercial Officer | A | — | — |
| 2025-02-20 | MICHELLE ROBERTSON | EVP, Chief Financial Officer | A | — | — |
| 2025-01-02 | Robert J. Spiegel | Director | A | — | — |
| 2024-11-12 | Joseph Eid | EVP, Research and Development | A | — | — |
| 2024-10-01 | Robert J. Spiegel | Director | A | — | — |
| 2024-09-09 | James Ziegler | EVP, Chief Commercial Officer | A | — | — |
| 2024-07-10 | ANDREW J GRETHLEIN | EVP, Chief Operating Officer | MIXED | — | — |
| 2024-06-28 | Robert J. Spiegel | Director | A | — | — |
| 2024-06-12 | Anil Kapur | EVP, Corp Strategy & CCO | MIXED | — | — |
| 2024-06-12 | Faye Feller | EVP, Chief Medical Officer | MIXED | — | — |
| 2024-06-07 | ANDREW J GRETHLEIN | EVP, Chief Operating Officer | A | — | — |
| 2024-06-07 | Anil Kapur | EVP, Corp Strategy & CCO | A | — | — |
| 2024-06-07 | Faye Feller | EVP, Chief Medical Officer | A | — | — |
| 2024-06-07 | MICHELLE ROBERTSON | EVP, Chief Financial Officer | A | — | — |
| 2024-06-07 | JOHN A SCARLETT | Chairman, President and CEO | A | — | — |
| Insider | Role | Shares Held | Value |
|---|---|---|---|
| — | President, Interim CEO, CFO | 765,092 | — |
| — | SVP, Chief Scientific Officer | 589,331 | — |
| — | EVP, Chief Financial Officer | 515,839 | — |
| — | President and CEO | 504,560 | — |
| — | Director | 485,970 | — |
| — | SVP, Corp Transactions | 484,823 | — |
| — | EVP, Corp Strategy & CCO | 421,875 | — |
| — | Director | 353,122 | — |
| — | SVP Alliance Mgmt & Operations | 331,213 | — |
| — | VP, CSO Telomerase Tech | 223,682 | — |
| — | EVP, Chief Legal Off & Sec | 217,624 | — |
| — | Director | 205,810 | — |
| — | Director | 186,511 | — |
| — | SVP Corp Dev | 185,000 | — |
| — | EVP, Chief Medical Officer | 155,400 | — |
| — | Director | 154,301 | — |
| — | Chairman, President and CEO | 137,500 | — |
| — | Director | 130,527 | — |
| — | Director | 109,047 | — |
| — | EVP, Chief Commercial Officer | 100,000 | — |
| — | EVP, R&D, Chief Med Officer | 94,796 | — |
| — | Director | 73,710 | — |
| — | Director | 62,751 | — |
| — | Director | 61,564 | — |
| — | President, Oncology | 52,510 | — |
Form 4 reports a change in beneficial ownership by an officer, director or 10%+ holder, and must be filed within two business days of the transaction — so this is close to real time, unlike the 45-day-lagged 13F institutional data.
Transaction codes matter more than the raw buy/sell count. Code P is an open-market purchase — an insider choosing to buy with their own money, which is the signal most research treats as informative. Code S is a sale, but sales are frequently pre-scheduled under a 10b5-1 plan or cover tax withholding on vesting equity, so a run of sales often says nothing directional. Codes A and M are grants and option exercises rather than open-market decisions.
Full filing history and per-insider positions are on the GERN quote page; the site-wide leaderboard is on the insider transactions hub.